Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study
Viruses · 2025
DOI: 10.3390/v17020251 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Viruses, 2025. Verfasst von Luca Rinaldi und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Health Sciences "Vincenzo Tiberio", Università degli Studi del Molise, 86100 Campobasso, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis Delta Virus, Hepatitis D, Chronic, Peptides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hepatitis D virus (HDV) infection remains a significant global health challenge due to its severity and high risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Bulevirtide, a novel HDV entry inhibitor, has shown promise in managing chronic hepatitis D by blocking viral entry into hepatocytes. This study evaluated the efficacy and safety of bulevirtide in reducing HDV RNA levels and improving liver function in a real-life cohort of Italian patients with HDV infection.
Methods
This multicenter prospective trial enrolled 108 consecutive patients with chronic HDV infection, from June 2023 to June 2024, who received 2 mg/day of bulevirtide in combination with a nucleoside/nucleotide analogue for hepatitis B virus (HBV) infection. Patients with any stage of liver fibrosis or compensated cirrhosis were included. Data collected included demographic and clinical characteristics, liver function tests, HDV RNA levels, and adverse events at baseline and 6 months.
Results
The virological response was achieved in 54.6% of patients (n = 59), with 36 demonstrating undetectable HDV RNA levels. Among responders, ALT levels decreased significantly from 67.0 U/mL [IQR 44.0–116.3] to 31.5 U/mL [IQR 24.0–36.5, p = 0.001], and AST levels from 66.0 U/mL [IQR 46.5–91.0] to 32.5 U/mL [IQR 28.0–38.0, p = 0.021]. Median HDV RNA dropped from 29,800 IU/mL [IQR 3100–375,000] to 0 IU/mL [IQR 0–291, p < 0.001]. No significant predictors of response emerged. Mild adverse events, including pruritus (5.6%) and injection-site reactions (1.9%) and flu-like syndrome (0.9) were reported, with no treatment discontinuation.
Conclusions
Bulevirtide effectively reduces HDV RNA levels and improves liver function with a favorable safety profile, offering a promising therapeutic option for chronic hepatitis D. Further large-scale studies are needed to confirm these findings and explore long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Health Sciences "Vincenzo Tiberio", Università degli Studi del Molise, 86100 Campobasso, Italy.
- Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
- Department of Medical Sciences, University of Turin, 10124 Turin, Italy.
- Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
- Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy.
- Infectious Diseases Unit, Sant'Anna e San Sebastiano Hospital, 81100 Caserta, Italy.
ORCID-Profile: Mauro Viganò, Alessia Ciancio, Alfredo Caturano, Alessandro Loglio, Letizia Marinaro, Carlo Acierno, Paolo Gallo, Valerio Rosato, Ferdinando Carlo Sasso, Giulio Petronio Petronio, Marco Distefano, Rodolfo Sacco, Alessandro Perrella
Zitieren
APA
Rinaldi, L., Viganò, M., Ciancio, A., Caturano, A., Messina, V., Niro, G. A., Capoluongo, N., Loglio, A., Marinaro, L., Marrone, A., Claar, E., Russello, M., Ciracì, E., Gentilucci, U. V., Pace Palitti, V., Acierno, C., Cosentino, C., Mormone, A., Cotugno, R., …, & Izzi, A. (2025). Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study. Viruses. https://doi.org/10.3390/v17020251
Vancouver
Rinaldi L, Viganò M, Ciancio A, Caturano A, Messina V, Niro GA, et al. Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study. Viruses. 2025. doi:10.3390/v17020251
BibTeX
@article{Rinaldi2025,
author = {Rinaldi, Luca and Viganò, Mauro and Ciancio, Alessia and Caturano, Alfredo and Messina, Vincenzo and Niro, Grazia Anna and Capoluongo, Nicolina and Loglio, Alessandro and Marinaro, Letizia and Marrone, Aldo and Claar, Ernesto and Russello, Maurizio and Ciracì, Emanuela and Gentilucci, Umberto Vespasiani and Pace Palitti, Valeria and Acierno, Carlo and Cosentino, Clelia and Mormone, Andrea and Cotugno, Rosa and Terracciani, Francesca and Gallo, Paolo and Cannavò, Maria Rita and Rosato, Valerio and Sasso, Ferdinando Carlo and Petrucciello, Chiara and Petronio Petronio, Giulio and Villone, Giovanni and Benanti, Francesco and Cariti, Giuseppe and Falbo, Elisabetta and Distefano, Marco and Sacco, Rodolfo and Perrella, Alessandro and Izzi, Antonio},
title = {Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17020251}
}
EUVIMED